Who depends on Baxalta
Baxalta appears in 2 disclosed customer relationships between 2014 and 2019.
Get an email when Baxalta's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Suppliers that depend on Baxalta
Listed companies whose annual report names Baxalta as a customer worth 10% or more of their revenue. If Baxalta cuts orders or switches supplier, these are the companies that feel it.
Formerly disclosed
| Supplier | Its revenue from this company | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Coherus OncologyCHRS | 99% | last FY 2016 | 3 years | FY 2016 · filed 28 Feb 2019 |
| Halozyme TherapeuticsHALO | 7% | last FY 2018 | 5 years | FY 2018 · filed 21 Feb 2019 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API